Admission glucose and risk of early death in non-diabetic patients with ST-segment elevation myocardial infarction: A meta-analysis

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1387-1394

  Zhao, Cheng Jin ^a   Hao, Zhen Xuan ^b   Liu, Rong ^c   Liu, Yang ^b  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Blood glucose; Meta analysis; Myocardial infarction

Indexed keywords

GLUCOSE; GLUCOSE BLOOD LEVEL;

ARTICLE; DEATH; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; AGED; ANALYSIS; BLOOD; COMPARATIVE STUDY; COMPLICATION; ELECTROCARDIOGRAPHY; FEMALE; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HYPERGLYCEMIA; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDY; RISK; SURVIVAL ANALYSIS; TIME FACTOR;

AGED; BLOOD GLUCOSE; ELECTROCARDIOGRAPHY; FEMALE; HOSPITAL MORTALITY; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT ADMISSION; PROGNOSIS; PROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84929428245     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894249     Document Type: Article

References (36)

1. Del OM, Merino-Torres JF, Argente M et al: Detection of glucose abnormalities in patients with acute coronary heart disease: study of reliable tools in clinical practice. J Endocrinol Invest, 2012; 35: 71–76
2. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet, 2000; 355: 773–78
3. Morrow DA, Antman EM, Charlesworth A et al: TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulatio, 2000; 102: 2031–37
4. Norhammar AM, Ryden L, Malmberg K: Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care, 1999; 22: 1827–31
5. Ishihara M, Kojima S, Sakamoto T et al: Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J, 2005; 150: 814–20
6. Wahab NN, Cowden EA, Pearce NJ et al: Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol, 2002; 40: 1748–54
7. Hoebers LP, Damman P, Claessen BE et al: Predictive value of plasma glucose level on admission for short and long term mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol, 2012; 109: 53–59
8. Ishihara M, Kagawa E, Inoue I et al: Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol, 2007; 99: 1674–79
9. Kosiborod M, Rathore SS, Inzucchi SE et al: Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation, 2005; 111: 3078–86
10. Hsu CW, Chen HH, Sheu WH et al: Initial serum glucose level as a prognostic factor in the first acute myocardial infarction. Ann Emerg Med, 2007; 49: 618–26
11. Keeley EC, Boura JA, Grines C: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 2003; 361: 13–20
12. Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010; 25: 603–5
13. Timmer JR, Hoekstra M, Nijsten MWN et al: Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with STsegment- elevation myocardial infarction treated with percutaneous coronary intervention. Circulation, 2011; 124: 704–11
14. Ergelen M, Uyarel H, Cicek G et al: Which is worst in patients undergoing primary angioplasty for acute myocardial infarction? Hyperglycaemia? Diabetes mellitus? Or both? Acta Cardiol, 2010; 65: 415–23
15. Planer D, Witzenbichler B, Guagliumi G et al: Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The HORIZONS-AMI trial. Int J Cardiol, 2013; 167: 2572–79
16. Gasior M, Pres D, Stasik-Pres G et al: Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Cardiol J, 2008; 15: 422–30
17. Vis MM, Sjauw KD, van der Schaaf RJ et al: In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes. Am Heart J, 2007; 154: 1184–90
18. Hoebers LP, Damman P, Claessen BE et al: Predictive value of plasma glucose level at admission for short and long term mortality in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol, 2012; 109: 53–59
19. De Monte A, Perkan A, Vitrella G et al: Impact of hyperglycemia on clinical outcome in patients undergoing percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). European Journal of Internal Medicine7th Congress of the European Federation of Internal Medicine Compendium of Oral Communications, 2008; 19: 45–46
20. Li Y, Qiu H, Wang W et al: Alteration of stress hormones and glucose levels after percutaneous coronary intervention in patients with acute myocardial infarction and its influence on prognosis. Chinese Journal of Practical Internal Medicine, 2010; 30: 61–63
21. Kosuge M, Kimura K, Kojima S et al: Effects of glucose abnormalities on inhospital outcome after coronary intervention for acute myocardial infarction. Circ J, 2005; 69: 375–79
22. Zhang JW, Zhou YJ, Cao SJ et al: Impact of stress hyperglycemia on in-hospital stent thrombosis and prognosis in nondiabetic patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis, 2013; 24: 352–56
23. Ekmekci A, Cicek G, Uluganyan M et al: Admission hyperglycemia predicts inhospital mortality and major adverse cardiac events after primary percutaneous coronary intervention in patients without diabetes mellitus. Angiology, 2014; 65: 154–59
24. Otten AM, Ottervanger JP, Timmer JR et al: Age-dependent differences in diabetes and acute hyperglycemia between men and women with ST-elevation myocardial infarction: a cohort study. Diabetol Metab Syndr, 2013; 5: 34
25. Shechter M, Merz CN, Paul-Labrador MJ, Kaul S: Blood glucose and platelet- dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol, 2000; 35: 300–7
26. Williams SB, Goldfine AB, Timimi FK et al: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation, 1998; 97: 1695–701
27. Marfella R, Siniscalchi M, Esposito K et al: Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care, 2003; 26: 3129–35
28. Esposito K, Nappo F, Marfella R et al: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation, 2002; 106: 2067–72
29. Allison SP, Tomlin PJ, Chamberlain MJ: Some effects of anaesthesia and surgery on carbohydrate and fat metabolism. 1969. Br J Anaesth, 1998; 81: 273–77
30. Eberli FR, Weinberg EO, Grice WN et al: Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res, 1991; 68: 466–81
31. Shah B, Amoroso NS, Sedlis SP: Hyperglycemia in nondiabetic patients presenting with acute myocardial infarction. Am J Med Sci, 2012; 343: 321–26
32. Ishihara M, Inoue I, Kawagoe T et al: Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J, 2003; 146: 674–78
33. Ishihara M, Inoue I, Kawagoe T et al: Effect of acute hyperglycemia on the ischemic preconditioning effect of prodromal angina pectoris in patients with a first anterior wall acute myocardial infarction. Am J Cardiol, 2003; 92: 288–91
34. Mehta SR, Yusuf S, Diaz R et al: Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA, 2005; 293: 437–46
35. Bucciarelli-Ducci C, Bianchi M, De Luca L et al: Effects of glucose-insulin-potassium infusion on myocardial perfusion and left ventricular remodeling in patients treated with primary angioplasty for ST-elevation acute myocardial infarction. Am J Cardiol, 2006; 98: 1349–53
36. Nikolaidis LA, Mankad S, Sokos GG et al: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004; 109: 962–65